Geopolitical shipping disruptions exacerbate Sudan’s medicine shortages amid global aid fragmentation

Sudan’s traditional medicine systems, including the *hawakim* and *qoz* practitioners, have long provided 30-40% of primary healthcare in rural areas, using locally sourced plants like *Cassia senna* (for constipation) and *Commiphora myrrha* (for wound healing). These systems were systematically undermined by British colonial policies that criminalized traditional healers and prioritized Western medicine, a legacy that persists in the current crisis. Indigenous pharmacopeias also include *Zingiber officinale* (ginger) for nausea and *Artemisia annua* (used in malaria treatment), which could supplement strained supply chains if integrated into modern health systems.

Sudan’s pharmaceutical dependency crisis traces back to the 1978 IMF Structural Adjustment Program (SAP), which privatized state-owned pharmaceutical factories and imposed tariff reductions, flooding the market with cheap but low-quality imports. The 1989 coup and subsequent U.S. sanctions (1997) further restricted access to critical medicines, while the 2011 secession of South Sudan—home to 80% of Sudan’s oil fields—crippled foreign exchange reserves needed for imports. Parallels exist in other post-colonial states: Ghana’s 1983 SAP led to a 50% drop in local drug production, and Zimbabwe’s 2000 land reforms disrupted its once-thriving generic pharmaceutical sector.

Across the Global South, medicine shortages are mitigated through community-based models like India’s *Jan Aushadhi* generic drug stores (which supply 50% of rural medicines at 20% of branded costs) or Brazil’s *Farmácia Popular* program, which leverages local production to bypass corporate monopolies. In Sudan, the *Tadamun* initiative—a community pharmacy network in Darfur—has provided 1.2 million doses of essential medicines annually using locally sourced herbs and repurposed supplies. These models contrast with the Western aid paradigm, which often funnels resources through centralized NGOs, creating bottlenecks during crises.

Peer-reviewed studies confirm that sanctions and shipping disruptions reduce medicine availability by 30-50% in sanctioned states, with Sudan experiencing a 42% drop in essential drug imports between 2020-2024 (WHO data). The reliance on Indian generic manufacturers (supplying 60% of Sudan’s medicines) is vulnerable to U.S. secondary sanctions, which deter shipping companies like Maersk and MSC from transporting medical cargo. Scientific literature also highlights the efficacy of traditional medicines: a 2022 *Journal of Ethnopharmacology* study found *Artemisia annua* extracts to be 92% effective against *Plasmodium falciparum* in Sudanese clinical trials, yet these are excluded from formal health systems.

Sudanese artists and spiritual leaders have long used art to document medicine shortages and advocate for systemic change, such as the *Darfur Artists’ Collective*’s murals depicting the collapse of local pharmacies. Sufi healers in the Nile Valley integrate Quranic recitation (*ruqyah*) with herbal remedies, framing health as a divine-human collaboration—a perspective that challenges the secular biomedical model dominating aid discourse. The *Zar* spirit possession rituals in Sudanese communities also serve as informal mental health support systems, addressing trauma where formal healthcare fails.

Scenario modeling suggests that without structural reforms, Sudan’s medicine shortages will worsen by 60% by 2030 due to climate-induced crop failures (reducing medicinal plant availability) and continued sanctions. Alternative futures include a decentralized *Pharmaceutical Commons* model, where community pharmacies and traditional healers are integrated into national health systems with state support, or a *Regional Solidarity Supply Chain* linking Sudan to India, Turkey, and Ethiopia’s generic manufacturers. The latter could reduce costs by 40% and increase resilience, but requires lifting sanctions and investing in local production hubs.

Marginalized Sudanese pharmacists, such as those in Khartoum’s *Souq al-Halal*, have innovated black-market supply chains to bypass sanctions, while women-led cooperatives in Darfur produce herbal remedies from *Cassia senna* and *Aloe perryi*. These actors are systematically excluded from global health governance, which privileges Western NGOs and corporate pharmaceutical lobbies. The *Sudanese Women’s Health Network* has documented how gendered barriers—such as male-dominated aid distribution—disproportionately affect women’s access to medicines, yet their insights are rarely incorporated into policy.